AbbVie stock down 1.8% in premarket trade after failure of glioblastoma drug trial

Shares of AbbVie Inc. ABBV, +0.08% fell 1.8% in premarket trade after the company announced that interim data from a Phase 3 trial of glioblastoma drug Depatux-M did not show any survival benefit to patients.